OmniAb Q3 Revenue $4.0M, Raises 2026 Revenue Guidance to $35-39M
OABI has more than doubled off its 52-week low of $1.3.
Summary
OmniAb reported Q3 2026 revenue of $4.0 million versus $2.2 million a year ago and raised full-year revenue guidance to $35-39 million from $32-36 million, with year-end cash now expected at $53-57 million.
Key Events · Earnings and Guidance · OABI
-
Q3 Revenue Doubles, Guidance Raised
Q3 2026 revenue was $4.0 million versus $2.2 million a year ago; full-year 2026 revenue guidance rose to $35-39 million from $32-36 million.
-
Cash Outlook Lifted to $53-57M
OmniAb held $64.2 million in cash, cash equivalents and short-term investments at September 30, 2026, and now expects to end the year with $53-57 million versus $49-53 million previously.
-
Cost Guidance Trimmed
Costs and operating expenses guidance was lowered to $83-87 million from $84-88 million, and cash costs and operating expenses to $50-54 million from $51-55 million.
-
Lilly Ion Channel Deal Up to $370M
A new global collaboration and license agreement with Eli Lilly for an ion channel program carries an up-front payment plus up to $370 million in research, development and commercial milestones and tiered royalties.
Analysis · OABI · Industrial Applications And Services
OmniAb's Q3 revenue of $4.0 million was up from $2.2 million a year ago, and nine-month revenue of $31.8 million already dwarfs the $10.3 million booked in all of the first nine months of 2025, largely on milestone payments. Management raised full-year revenue guidance to $35-39 million from $32-36 million and lifted the year-end cash outlook to $53-57 million from $49-53 million, while trimming the cost outlook. The company ended September with $64.2 million in cash and short-term investments, so the raised cash target extends runway rather than signaling a need to raise capital. The quarter also brought a new Eli Lilly ion channel collaboration worth up to $370 million in milestones, an expanded commercial launch of the xPloration platform, and the OmniTides peptide offering — all of which support the durability of the revenue base.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, OABI was trading at $5.00 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $760.4M. The 52-week trading range was $1.30 to $5.43. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.